Formulation of liposomal derivatives of phenylalanine
The invention relates to pharmaceutical formulations of phenylalanine derivatives and to the use thereof as urokinase inhibitors, in particular for the treatment of malignant tumors and of tumor metastases.
1 - 27 . (canceled)
28 . A pharmaceutical liposomal formulation, characterized in that it comprises as active ingredient a 3-amidino- or 3-guanidino phenylalanine derivative which is effective as urokinase inhibitor, where the active ingredient is present in a proportion by weight of 0.5-100 based on the total weight of the formulation.
29 . The formulation as claimed in claim 28 , characterized in that the urokinase inhibitor is selected from Na-(2,4,6-triisopropylphenyl sulfonyl)-3-amidino-(D,L)-henylalanine-4-ethoxy carbonylpiperazide, the L enantiomer thereof or a pharmaceutically suitable salt of these compounds.
30 . The formulation as claimed in claim 28 , characterized in that the urokinase inhibitor is selected from Na-(2,4,6-triisopropylphenyl sulfonyl)-3-guanidino-(D,L)-phenylalanine-4 ethoxycarbonylpiperazide, the L enantiomer thereof or a pharmaceutically suitable salt of these compounds.
31 . The formulation as claimed in claim 28 , characterized in that the active ingredient is present in a proportion by weight of 2-50.
32 . The formulation as claimed in claim 28 , characterized in that it has a pH in the range 5.5-9.0.
33 . The formulation as claimed in claim 28 , characterized in that it comprises phospholipids in a proportion by weight of 4.5-400 based on the total weight of the formulation.
34 . The formulation as claimed in claim 28 , characterized in that it comprises phospholipids selected from neutral phospholipids, anionic phospholipids and combinations thereof.
35 . The formulation as claimed in claim 28 , characterized in that it comprises at least one anionic phospholipids such as, for example, phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol, phosphoinositol or esterified derivatives thereof.
36 . The formulation as claimed in claim 34 , characterized in that it comprises phosphatidylcholine and dimyristoylphosphatidyl glycerol in a ratio of 70:30 by weight.
37 . The formulation as claimed in claim 28 , characterized in that it additionally comprises a membrane-stabilizing component such as, for example, cholesterol, in a proportion by weight of up to 5% based on the total weight of the formulation.
38 . The formulation as claimed in claim 28 characterized in that it additionally comprises a cryoprotectant.
39 . The formulation as claimed in claim 38 , characterized in that the cryoprotectant is present in a proportion by weight of up to 150, preferably 5-150, based on the total weight of the formulation.
40 . The formulation as claimed in claim 38 , characterized in that the cryoprotectant is selected from carbohydrates or/and sugar alcohols.
41 . The formulation as claimed in claim 28 , characterized in that the average diameter of liposomes is not greater than 500 nm.
42 . The formulation as claimed in claim 41 , characterized in that the average diameter of liposomes is 100-200 nm.
43 . The formulation as claimed in claim 28 , characterized in that the liposomes are unilamellar liposomes.
44 . The formulation as claimed in claim 28 , for parenteral administration.
45 . The formulation as claimed in claim 44 for intravenous injection.
46 . The formulation as claimed in claim 44 for infusion.
47 . The formulation as claimed in claim 44 for subcutaneous injection.
48 . The formulation as claimed in claim 44 for subcutaneous injection
49 . The formulation as claimed in claim 28 in dehydrated form.
50 . The formulation as claimed in 28 for controlling urokinase-associated disorders.
51 . The formulation as claimed in claim 50 for controlling tumors.
52 . The formulation as claimed in claim 51 for controlling carcinomas of the breast, pancreatic carcinomas or/and the formation of metastases.
53 . The use of a formulation as claimed in claim 28 in combination with cytostatic agents.